Sex differences in risk factor control of treated hypertensives: A national primary healthcare-based study in Sweden

European Journal of Preventive Cardiology

Volumn 15, Issue 3, 2008, Pages 258-262

  Journath, Gunilla ^a,b   Hellénius, Mai Lis ^a   Petersson, Ulla ^c   Theobald, Holger ^a   Nilsson, Peter M ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MERCK RESEARCH LABORATORIES   (United States)

^c LINKÖPING UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cholesterol; hypertension; primary healthcare; risk factors; sex

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PUBLIC HEALTH; RISK FACTOR; SEX DIFFERENCE; SWEDEN; ADULT; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; HEALTH SERVICE; HEALTH SURVEY; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITAL PHYSICIAN; MAJOR CLINICAL STUDY; MICROALBUMINURIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PRIMARY HEALTH CARE; RISK FACTORS; SEX FACTORS; SWEDEN;

EID: 56149112987     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e3282f37a45     Document Type: Article

References (31)

1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571–1576.
2. World Health Organization (WHO)/lnternational Society of Hypertension (ISH). Statement on hypertension management. J Hypertens 2003; 21: 1983–1992.
3. European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–1187.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
5. The Swedish Council on Technology Assessment in Health Care. Moderately elevated blood pressure. Report volumes 1–3. Stockholm: Swedish Council on Technology Assessment in Health Care; 2004.
6. Nilsson P, Andersson DKG, Andersson P-E, Schwan A, Östlind B, Malmborg R et al. Cardiovascular risk factors in treated hypertensives: a nation-wide, cross-sectional study in Sweden. J Intern Med 1993; 233: 239–245.
7. Kjellgren K, Ahlner J, Dahlöf B, Gill H, Hedner T, Säljö R et al. Perceived symptoms amongst hypertensive patients in routine clinical practice-a population-based study. J Intern Med 1998; 244: 325–332.
8. Cederholm J, Nilsson PM, Anderberg C-P, Fröberg L, Pettersson U, for the Q-Heart Study Group. Blood pressure and other cardiovascular risk factors among treated hypertensives in Swedish primary health care. Scand J Prim Health Care 2002; 20: 224–229.
9. Journath G, Nilsson PM, Petersson U, Paradis B-A, Theobald H, Erhardt L. Hypertensive smokers have a worse cardiovascular risk profile than non-smokers in spite of treatment: a national study in Sweden. Blood Press 2005; 14: 144–150.
10. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
11. Daniel WW. Biostatistics: a foundation for analysis in the health sciences. 6 ed. New York: Wiley; 1995.
12. Montgomery DC. Design and analysis of experiments. 3 ed. New York: Wiley; 1991.
13. Persson M, Carlberg B, Mjorndal T, Asplund K, Bohlin J, Lindholm L. 1999 WHO/ISH guidelines applied to a 1999 MONICA sample from northern Sweden. J Hypertens 2002; 20: 29–35.
14. Weinehall L, Öhgren B, Persson M, Stegmayr B, Boman K, Hallmans G et al. High remaining risk in poorly treated hypertension, the ‘rule of halves’ still exists. J Hypertens 2002; 20: 2081–2088.
15. Hedblad B, Nerbrand C, Ekesbo R, Johansson L, Midlo P, Brunkstedt I et al. High blood pressure despite treatment: results from a cross-sectional primary healthcare-based study in southern Sweden. Scand J Prim Health Care 2006; 24: 224–230.
16. Joffres MR, Hamet P, MacLean DR, Ultalien GJ, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens 2001; 14: 1099–1105.
17. Westheim A, Klemetsrud T, Tretli S, Stoikke HP, Oisen H. Blood pressure levels in treated hypertensive patients in general practice in Norway. Blood Press 2001; 10: 37–42.
18. Primatesta P, Poulter NR. Improvement in hypertension management in England: results from the Health Survey for England. J Hypertens 2006; 24: 1187–1192.
19. National Heart, Lung, and Blood Institute. The sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Bethesda, Maryland: U.S. Department of Health and Human Services, National Institutes of Health; NIH publication no.98–4080; 1997.
20. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206.
21. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004; 44: 1–7.
22. Luepker RW, Arnett DK, Jacobs DR, Duval SJ, Folsom AR, Armstrong C et al. Trends in blood pressure, hypertension control, and stroke mortality: the Minnesota Heart Survey. Am J Med 2006; 119: 42–49.
23. Kastarinen MJ, Antikainen RL, Laatikainen TK, Salomaa VV, Tuomilehto JO, Nissinen AM et al. Trends in hypertension care in eastern and south-western Finland during 1982–2002. J Hypertens 2006; 24: 829–836.
24. Van Wijk BLG, Klungel OH, Heerdink ER, de Boer A. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens 2004; 22: 1831–1837.
25. Berg CM, Lissner L, Aires N, Lappas G, Torén K, Wilhelmsen L et al. Trends in blood lipid levels, blood pressure, alcohol and smoking habits from 1985 to 2002: results from INTERGENE and GOT-MONICA. Eur J Cardiovasc Prev Rehab 2005; 12: 115–125.
26. De Simone G, Devereux RB, Daniels SR, Meyer RA. Gender differences in left ventricular growth. Hypertension 1995; 26: 979–983.
27. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993; 72: 310–313.
28. Bella JN, Palmieri V, Wachtell K, Liu JE, Gerdts E, Nieminen MS et al. Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. J Hum Hypertens 2004; 18: 411–416.
29. Writing Group for the Women's Health Initiatives Investigators. Risk and benefits of estrogens plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiatives randomized controlled trial. JAMA 2002; 288: 321–333.
30. Verhave JC, Hillege HL, Burgerhof JG, Navis G, de Zeeuw D, de Jong PE, for the PREVEND study group. Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J Am Soc Nephrol 2003; 14: 1330–1335.
31. Luchner A, Bröckel U, Muscholl M, Hense HW, Döring A, Riegger G et al. Gender-specific differences of cardiac remodelling in subjects with left ventricular dysfunction: a population-based study. Cardiovasc Res 2002; 53: 720–727.